Bayer's 2024 annual results showed a 2.2% sales decline, with only free cash flow improving significantly. Read why BAYZF ...

The FDA accepts and grants priority review to BAYRY's sNDA for Kerendia to treat patients with a common form of heart failure ...

The US Food and Drug Administration (FDA) accepted and granted Priority Review designation for Bayer’s (BAYN: DE) supplemental new drug application (sNDA) for a new indication for Kerendia (finerenone ...

Regulators are expected to make a decision in the third quarter of 2025 on Kerendia to treat patients with heart failure with ...

Berlin: Bayer has announced that the Company has received Priority Review designation from the U.S. Food and Drug ...

Bayer has won U.S. Food and Drug Administration priority review for its application seeking expanded approval of its kidney-disease drug Kerendia in certain people with heart failure.

Avado, a leading provider of professional learning, is introducing CIPD Level 5 Plus ? a premium offering for those pursuing their CIPD qualification. Building on the success of Avado's existing CIPD ...

Huawei, UNESCO, and government partners officially announced the completion of Phase II of the Kenya DigiSchool Connectivity Project, which connected 21 schools to the Internet, including 6 schools ...

In a report released on March 5, Christian Faitz from Kepler Capital maintained a Hold rating on Bayer (0P6S – Research Report), with a price ...

Bayer’s fourth-quarter earnings were in line ... Pharmaceuticals grew by 2.4%, with new drugs Nubeqa (prostate cancer) and Kerendia (metabolic disease) posting strong adjusted growth of 73% ...

BAYRY's fourth-quarter earnings match expectations. Revenues top estimates, driven by the strong performance of its ...

The company is working to expand the labels of its key drugs, Nubeqa and Kerendia, which should boost growth. Successful development of additional drugs is imperative for Bayer amid multiple ...